Thorlef Spickschen
Presidente en German Kidney Foundation .
Cargos activos de Thorlef Spickschen
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Biovision AG | Director/Miembro de la Junta | 18/05/2010 | - |
Innovation GmbH | Director/Miembro de la Junta | 18/05/2010 | - |
Ruprecht-Karls-Universität Heidelberg | Director/Miembro de la Junta | 13/01/2011 | - |
German Kidney Foundation | Presidente | - | - |
Director/Miembro de la Junta | - | - |
Historial de carrera de Thorlef Spickschen
Antiguos cargos conocidos de Thorlef Spickschen.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
CLOVIS ONCOLOGY, INC. | Director/Miembro de la Junta | 20/04/2009 | 10/07/2023 |
Independent Dir/Board Member | 20/04/2009 | 10/07/2023 | |
BIOTEST AG | Presidente | 01/01/2005 | 10/05/2012 |
Pharmion Corp.
Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Director/Miembro de la Junta | 01/12/2001 | 07/03/2008 |
BASF Pharma Ltd.
BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million. | Director Ejecutivo | 01/01/1994 | 01/01/2001 |
Presidente | 01/01/1994 | 01/01/2001 | |
Knoll AG
Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The company is based in Haren, Germany. | Director Ejecutivo | 01/01/1994 | 01/01/2001 |
Presidente | 01/01/1994 | 01/01/2001 | |
░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░░ ░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Formación de Thorlef Spickschen.
Universität zu Köln | Doctorate Degree |
Estadísticas
Internacional
Alemania | 8 |
Estados Unidos | 4 |
Suiza | 4 |
Operativa
Director/Board Member | 7 |
Chairman | 4 |
Chief Executive Officer | 4 |
Sectorial
Health Technology | 7 |
Consumer Services | 3 |
Commercial Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
BIOTEST AG | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
Empresas privadas | 10 |
---|---|
Pharmion Corp.
Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Health Technology |
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | Commercial Services |
Biovision AG | |
Innovation GmbH | |
BASF Pharma Ltd.
BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million. | Health Technology |
Knoll AG
Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The company is based in Haren, Germany. | Health Technology |
Roche Diagnostics GmbH
Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999. | Commercial Services |
German Kidney Foundation | |
Boehringer Mannheim GmbH |
- Bolsa de valores
- Insiders
- Thorlef Spickschen
- Experiencia